Cybin IRL Limited
USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07B (General Methods OF Organic CHEMISTRY; Apparatus Therefor).
The verdict
According to USPTO PatentsView, Cybin ranks #31,341 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.
- #31,341
- of 49,997 US assignees by volume
- Top 25%
- by Innovation Score (44.5/100)
- 13.8
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R31341 · Foreign Corporation #31,341 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 8 grants
- MID-PACK #31,341/49,997
- PHOTO-FINISH Curegenix
- CPC-NARROW C07B · 6 areas
- INNOV-PAR 44.5/100
- CLAIMS-RICH 13.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2023–2025 · 3y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Curegenix, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Cybin’s 44.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Cybin
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Cybin IRL · this assignee
Cybin IRL · this assignee
45 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Cybin's Innovation Score is 44.5/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Cybin?
Each dot is one of Cybin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cybin’s own 13.8 claims/patent is at or below the 18.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Cybin's grants concentrate
Cybin IRL Limited is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07B (General Methods OF Organic CHEMISTRY; Apparatus Therefor). By volume, Cybin sits between Curegenix, Inc. and Cyrano Therapeutics, Inc..
Cybin's three-year grant acceleration
Cybin IRL Limited shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Cybin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Curegenix
Curegenix, Inc.
8 patents
- Curvo Medical
Curvo Medical, Inc.
8 patents
- Curza Global
Curza Global, LLC
8 patents
- Cyber Atomics
Cyber Atomics, Inc.
8 patents
- Cyclomedia Techno…
Cyclomedia Technology B.V.
8 patents
- Cylite Pty
Cylite Pty Ltd
8 patents
- Cypris Medical
Cypris Medical, Inc.
8 patents
- Cyrano Therapeuti…
Cyrano Therapeutics, Inc.
8 patents
- Cybin IRL ◀
Cybin IRL Limited
8 patents
What this shows Cybin holds 8 patents at rank #31,342, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cybin
By rank, the assignees closest to #31,342 in granted patent volume.
- Curegenix, Inc. #31,338 · 8 patents
- Curvo Medical, Inc. #31,339 · 8 patents
- Curza Global, LLC #31,340 · 8 patents
- Cyber Atomics, Inc. #31,341 · 8 patents
- Cyclomedia Technology B.V. #31,343 · 8 patents
- Cylite Pty Ltd #31,344 · 8 patents
- Cypris Medical, Inc. #31,345 · 8 patents
- Cyrano Therapeutics, Inc. #31,346 · 8 patents
Leaders in C07B (General Methods OF Organic Chemistry)
Other assignees with the most granted patents in Cybin's primary technology class.
Cybin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 3 | 37.5% |
| 2024 | 3 | 37.5% |
| 2025partial year | 2 | 25.0% |
Which technologies does Cybin IRL Limited patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Cybin IRL Limited's patent record in context - here's where to go next.
- Cybin IRL Limited's lead technology class is C07B (General Methods OF Organic CHEMISTRY; Apparatus Therefor), 100% of its portfolio - see every assignee active in that class. Explore C07B
- Ranked #31,341 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Cybin IRL Limited against Curegenix, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 44.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.